Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
$182.84
-$3.85(-1.73%)
At close: 4:00 PM EST
$182.84
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$125.10 - $228.29
Previous CloseN/A
Volume330.38K
Average Volume (3M)940.23K
Market Cap
$13.96B
Enterprise Value$16.77B
Total Cash (Recent Filing)$468.89M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)24.7
Beta1.01
Next Earnings
Feb 25, 2026EPS Estimate
3.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding76,359,930
10 Day Avg. Volume847,226
30 Day Avg. Volume940,233
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)1.82
Price to Sales (P/S)2.09
P/FCF Ratio15.46
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit7.71
Enterprise Value/Ebitda14.22
Forecast
1Y Price Target
$199.67Price Target Upside9.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)13.08
Revenue Forecast (FY)$8.07B
Bulls Say, Bears Say
Bulls Say
Leadership TransitionBarry Balfe has been settling into his new position as CEO nicely, allowing for a smooth transition due to his critical role and relationships with large Pharma as COO.
Market PositionThe company believes it has had good gross bookings as the market recovers, highlighting its strong competitive position and suggesting recent headwinds are transient.
Strategic PartnershipsICON is a global CRO that should benefit from its strategic partnerships with large pharma and growing exposure in the faster-growing biopharma end-market over time.
Bears Say
HeadwindsMacro and ongoing idiosyncratic headwinds are likely to persist over the next 2-3 quarters, weighing on its performance.
Margin PressureManagement expects margin pressure from higher pass-through costs to continue, impacting profitability.
Revenue ImpactICON is continuing to work through cancellations, which will have an impact on revenue in the near term.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $125.10 and its highest was $228.28 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $13.96B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Feb 25, 2026 which is in 58 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Oct 22, 2025. The company reported $3.31 earnings per share for the quarter, beating the consensus estimate of $3.301 by $0.009.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.31.
How many shares outstanding does Icon plc have?
Icon plc has 76,359,930 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.31 in its last earnings report, beating expectations of $3.301. Following the earnings report the stock price went down -6.542%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$199.67 (9.20% Upside)
$199.67 (9.20% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 216.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.49%
12-Months-Change
Fundamentals
Return on Equity
6.27%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ICON plc's performance. While there were strong business awards and strategic investments in technology, the company faced challenges with elevated cancellations and pricing pressures affecting margins. The overall outlook remains cautiously optimistic, with expectations of normalized cancellation levels and continued technological advancements.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$199.67
▲(9.20% Upside)
Technical Analysis
Ownership Overview
0.40% Insiders
31.12% Mutual Funds
48.94% Other Institutional Investors
17.51% Public Companies and
Individual Investors